CluenexThermo Fisher Scientific Inc TMO
Thermo Fisher Scientific Inc scores average on business quality (4.5 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Thermo Fisher Scientific Inc does
Thermo Fisher Scientific supplies life sciences tools, analytical instruments, and biotech manufacturing services. Labs, hospitals, and pharmaceutical companies pay them to provide the consumables and equipment required for drug development and clinical testing.
- What it does best
Thermo Fisher scales a massive portfolio of proprietary lab consumables and analytical instruments. With a gross margin of 40.9% compared to Danaher's 58.6%, its sheer breadth of scale locks in global research institutions through deep workflow integration that is hard to replace.
- The main risk
A debt-to-equity ratio of 0.7 and total debt of $39.4 billion expose the balance sheet to refinancing friction if cash generation slows down from its current free cash flow of $7.3 billion.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin stands at 18.3% with a net margin of 15.0%, showing steady cash generation from its diverse base of scientific products.
An operating margin sector percentile of 56 reflects middle-of-the-pack economics, limited by heavy competition in analytical instruments.
Revenue growth crawls at 3.9%, putting the company in the bottom quartile of its sector at the 24th percentile as post-pandemic demand normalizes.
Total debt sits at $39.4 billion with interest coverage at 5.8x, while free cash flow reaches $7.3 billion, keeping the balance sheet at a stable baseline.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
2 sold $10.7M outside pre-planned sales.
Our sealed record on TMO
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Thermo Fisher Scientific Inc scores average on the Cluenex quality check (4.5 of 10), measured against its own industry. Profitability is fair, moat fair, growth slow and financial health fair.
In the last 90 days of SEC Form 4 filings: 2 sold $10.7M outside pre-planned sales.
Oct 21, 2026, before the open.
See TMO today
- Today's verdict on TMO, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Thermo Fisher Scientific Inc (TMO)”, https://cluenex.com/stocks/tmo/, data as of Oct 10, 2026.